May 03, 2020
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
Jan 13, 2020
First Japanese Patients Randomized In Corvia Medical's REDUCE LAP-HF II Global Clinical Trial For Heart Failure
Sep 23, 2019
BioVentrix Announces Study Design for REVIVE-HF: Randomized Controlled Trial (RCT) in Europe
Sep 04, 2019
A New Treatment Option for Diabetic Cardiomyopathy
May 22, 2019
Cardiology Society Gets to the "Heart" of Hypertrophic Cardiomyopathy
Mar 04, 2019
National Institutes of Health awards Geisinger over $3.1 million for research of sudden cardiac death
Feb 01, 2019
My Gene Counsel Launches Cardiovascular Content for February's Heart Awareness Month
Aug 22, 2018
Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy
Aug 10, 2018
Hypertrophic Cardiomyopathy Epidemiology Forecast Markets 2018-2028 by Gender & 5 Year Age Cohort
May 04, 2018
Renova Therapeutics: JACC: Basic to Translational Science publishes article comparing effects of urocortin 2 versus urocortin 3 gene transfer on left ventricular function and glucose disposal
May 03, 2018
Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy
Feb 26, 2018
Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
Nov 15, 2017
Preclinical Data Demonstrates Potential of Eidos Therapeutics' Lead Compound for the Treatment for Transythyretin Amyloidosis
Nov 09, 2017
Eidos Therapeutics to Present Data on its Potential Treatment for Transthyretin Amyloidosis at the American Heart Association
Oct 27, 2017
BioVentrix Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2017
Oct 19, 2017
HeartSciences Launches Breakthrough ECG Technology at the Canadian Cardiovascular Congress
Oct 05, 2017
Children's Cardiomyopathy Foundation Supports Congressman Pallone's Legislation to Expand Research and Education on Children's Heart Disease
Oct 04, 2017
BioVentrix Announces First Patient Enrolled in the U.S. arm of IDE Study of the Revivent TC(TM) TransCatheter Ventricular Enhancement Treatment
Sep 28, 2017
Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer
Sep 18, 2017
BioVentrix announces the 1st Revivent TC(TM) TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment at the University Heart Center Zurich in Switzerland